While it is not known what the homeostatic balance levels are between pro-inflammatory and anti-inflammatory T cells, this study indicates the necessity to restore a balance in order to halt chronic T2D and inflammation. ‘The true need for our observations is the indication that altering stability among immune system cells could be a fundamentally novel treatment for T2D-associated inflammation and perhaps insulin resistance,’ said Nikolajczyk.. Altering balance among immune system cells could hold prospect of T2D-associated inflammation treatment Experts from Boston University School of Medicine have got demonstrated that one T cells require input from monocytes in order to maintain their pro-inflammatory response in people who have type 2 diabetes .All rights reserved.
Clinical data of CU-201, CUDC-101 presented at EORTC-NCI-AACR Symposium Curis, Inc. , a drug development business wanting to develop next era targeted small molecule drug candidates for tumor treatment, today announced the presentation of data in two poster presentations at the 22nd EORTC-NCI-AACR Symposium on ‘Molecular Targets and Cancer tumor Therapeutics,’ held in Berlin, Germany, 16-19 November. One display is titled ‘Anti-Tumor Activity of CU-201, an Inhibitor of HDAC, SFK and Abl Kinases’ and was presented by Rudi Bao, M.D., Ph.D., Curis’ Senior Director of Oncology on November 17th.